Cupid announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 24 February 2026.Powered by Capital Market - Live News

Net profit of Cupid rose 196.30% to Rs 32.83 crore in the quarter ended December 2025 as against Rs 11.08 crore during the previous quarter ended December 2024. Sales rose 101.73% to Rs 93.50 crore in the quarter ended December 2025 as against Rs 46.35 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales93.5046.35 102 OPM %36.6824.55 - PBDT44.5815.39 190 PBT43.2714.10 207 NP32.8311.08 196 Powered by Capital Market - Live News

The board of Cupid has approved a proposal for the issuance of bonus equity shares in the ratio of 4:1, subject to the receipt of requisite shareholder and regulatory approvals, as applicable. Under the proposed bonus issue, eligible shareholders will receive four (4) fully paid-up equity shares for every one (1) equity share held by them as on the record date, which will be announced in due course. Powered by Capital Market - Live News

Cupid announced that it has received CE (EU IVDR) Certification for two in-vitro diagnostic (IVD) products � the CupiKIT HIV 1&2 Antibody Test Kit and the CupiKIT Hepatitis B Surface Antigen (HBsAg) Test Kit. The certifications have been granted under the European Union In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR), among the most stringent regulatory standards globally. These approvals enable Cupid Limited to market the certified products across the European Economic Area (EEA) and other CE recognized international markets.Powered by Capital Market - Live News

Cupid will hold a meeting of the Board of Directors of the Company on 29 January 2026.Powered by Capital Market - Live News